ARUP's Laboratory Test Directory
| 0080428: Alpha Fetoprotein, Plasma or Serum (Tumor Marker) |
| Test Mnemonic: AFP TM | |
|
Methodology: Electrochemiluminescent Immunoassay
Performed: Sun-Sat Reported: Within 24 hours |
| Specimen Required: | |
|
Collect: One 4 mL PST or SST. Also acceptable: lavender (EDTA) or pink (K2EDTA).
Transport: 1 mL plasma or serum at 2-8°C. (Min: 0.5 mL) Submit specimen in an ARUP Standard Transport Tube. Pediatric Collection/Transport: 0.2 mL plasma or serum at 2-8°C. Remarks: Allow specimen to clot completely at room temperature. Separate serum or plasma from cells ASAP. Unacceptable Conditions: Grossly hemolyzed specimens. Stability: After separation from cells: Ambient: 8 hours; Refrigerated: 1 week; Frozen: 3 months |
|
| Reference Interval: |
|
0-14 days: 5,000-105,000 ng/mL 3 months: 11-300 ng/mL 15 days-30 days: 300-60,000 ng/mL 4 months: 5-200 ng/mL 1 month: 100-10,000 ng/mL 5 months: 0-90 ng/mL 2 months: 40-1,000 ng/mL 6 months and older: 0-15 ng/mL |
| Interpretive Data: | |
|
The Roche Modular E170 AFP method is used. Results obtained with different assay methods or kits cannot be used interchangeably. AFP is a valuable aid in the management of nonseminomatous testicular cancer patients when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased serum AFP concentrations have also been observed in ataxia telangiectasia, hereditary tyrosinemia, primary hepatocellular carcinoma, teratocarcinoma, gastrointestinal tract cancers with and without liver metastases, and in benign hepatic conditions such as acute viral hepatitis, chronic active hepatitis, and cirrhosis. This result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable in pregnant females.
|
| Note: | |
| Adult males and nonpregnant females: 0-15 ng/mL |
| CPT Code(s): | |
| 82105 |